Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02729415 · ClinicalTrials.gov registry record · NA
Point-of-Care Adipose-derived Cells for Hair Growth
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02729415 is a NA study that has completed, run by University of Florida. The registered enrollment target is 8 participants.
The verdict
NCT02729415, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Androgenetic alopecia (AGA) is the most common form of hair loss and affects 50% and 23% of Caucasian men and women, respectively, over the age of 50. The percentage of men and women affected over the age of 70 increases to 80% and 60% of Caucasian men and women, respectively. Although alopecia is considered a minor dermatologic condition, it is seen as a serious condition with major life consequences by those with alopecia and has been associated with increased incidence of myocardial infarction, hypertension and hypercholesterolaemia. Androgenetic alopecia is associated with feelings of anxiety, depression and various personality disorders among men and women due to physical appearance. Depression, anxiety, aggressiveness, impaired quality of life and social inadequacy have been documented. The presence of alopecia in women is particularly stressful. ADSCs (Adipose Derived Stromal Cells), also called Stromal Vascular Fraction (SVF) cells, include regenerative cell populations derived from adipose tissue and thus are potentially important to multiple disease processes and therapeutic applications for the repair and regeneration of acute and chronically damaged tissues. It has been postulated that SVF cells may promote hair regeneration by increasing the hair-inducing ability of dermal papillae (DP) cells. The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF cells for the treatment of alopecia.
Interventions
- PROCEDURE Liposuction
- PROCEDURE Stromal Vascular Fraction Cells (SVF Cells) Injection
- OTHER Hair Measurements
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02729415
The ClinicalTrials.gov registry entry for NCT02729415 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Liposuction is the first listed.
NCT02729415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02729415 about?
NCT02729415 is a clinical study titled "Point-of-Care Adipose-derived Cells for Hair Growth". Androgenetic alopecia (AGA) is the most common form of hair loss and affects 50% and 23% of Caucasian men and women, respectively, over the age of 50. The percentage of men and women affected over the age of 70 increases to 80% and 60% of Caucasian men and women, respectively. Although alopecia is c...
What is the current status of trial NCT02729415?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2016-10. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT02729415?
The interventions under investigation include: Liposuction (PROCEDURE), Stromal Vascular Fraction Cells (SVF Cells) Injection (PROCEDURE), Hair Measurements (OTHER).
Who is sponsoring clinical trial NCT02729415?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.